Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience.

Andrea Sbrana; Elisa Biasco; Federico Paolieri; Erica Palesandro; Claudia Caserta; Roberto Iacovelli; Beatrice Detti; Daniele Santini; Alessandra Mosca; Franco Morelli; Giuseppe Fornarini; Ugo De Giorgi; Cristina Masini; Luca Galli

doi:10.21873/anticanres.12807

Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience.

Andrea Sbrana, Elisa Biasco, Federico Paolieri, Erica Palesandro, Claudia Caserta, Roberto Iacovelli, Beatrice Detti, Daniele Santini, Alessandra Mosca, Franco Morelli, Giuseppe Fornarini, Ugo De Giorgi, Cristina Masini, Luca Galli

Istituto Oncologico Candiolo

Research output: Contribution to journal › Article › peer-review

Abstract

The specific characteristics of patients who are most likely to benefit from pazopanib therapy are still uncertain. We report on the results of an Italian multicenter, retrospective analysis investigating the factors associated with longer response to first-line pazopanib in patients with metastatic renal cell carcinoma. Adult patients were considered if they had received treatment with pazopanib (800 mg/day) for >12 months in the first-line setting. In total, 112 patients were evaluated. Median duration of pazopanib treatment was 22.6 months (IQR 17.8 months). Median PFS was 22.6 months (95%CI= 20.2-25.0). Eighty-three patients (74.1%) had a PFS ≥18 months. Median OS was 32.9 months (95%CI=30.2-35.6). At statistical analysis, only PS score (1+ vs. 0) was significantly associated with PFS (HR=1.76; 95%CI=1.02-3.05; p=0.04). Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0.

Original language	Undefined/Unknown
Pages (from-to)	4913-4918
Number of pages	6
Journal	Anticancer Research
Volume	38
DOIs	https://doi.org/10.21873/anticanres.12807
Publication status	Published - Aug 1 2018

Keywords

Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors, therapeutic use
Carcinoma, Renal Cell, drug therapy
Disease-Free Survival
Female
Humans
Italy
Kidney Neoplasms, drug therapy
Male
Middle Aged
Pyrimidines, therapeutic use
Receptors, Vascular Endothelial Growth Factor, antagonists & inhibitors
Retrospective Studies
Sulfonamides, therapeutic use
first-line
mRCC
pazopanib
response

Access to Document

10.21873/anticanres.12807

Cite this

Sbrana, A., Biasco, E., Paolieri, F., Palesandro, E., Caserta, C., Iacovelli, R., Detti, B., Santini, D., Mosca, A., Morelli, F., Fornarini, G., De Giorgi, U., Masini, C., & Galli, L. (2018). Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. Anticancer Research, 38, 4913-4918. https://doi.org/10.21873/anticanres.12807

@article{d0fc6847f6fa4c9caf88a0bd212acc47,

title = "Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience.",

abstract = "The specific characteristics of patients who are most likely to benefit from pazopanib therapy are still uncertain. We report on the results of an Italian multicenter, retrospective analysis investigating the factors associated with longer response to first-line pazopanib in patients with metastatic renal cell carcinoma. Adult patients were considered if they had received treatment with pazopanib (800 mg/day) for >12 months in the first-line setting. In total, 112 patients were evaluated. Median duration of pazopanib treatment was 22.6 months (IQR 17.8 months). Median PFS was 22.6 months (95%CI= 20.2-25.0). Eighty-three patients (74.1%) had a PFS ≥18 months. Median OS was 32.9 months (95%CI=30.2-35.6). At statistical analysis, only PS score (1+ vs. 0) was significantly associated with PFS (HR=1.76; 95%CI=1.02-3.05; p=0.04). Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0.",

keywords = "Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors, therapeutic use, Carcinoma, Renal Cell, drug therapy, Disease-Free Survival, Female, Humans, Italy, Kidney Neoplasms, drug therapy, Male, Middle Aged, Pyrimidines, therapeutic use, Receptors, Vascular Endothelial Growth Factor, antagonists & inhibitors, Retrospective Studies, Sulfonamides, therapeutic use, first-line, mRCC, pazopanib, response",

author = "Andrea Sbrana and Elisa Biasco and Federico Paolieri and Erica Palesandro and Claudia Caserta and Roberto Iacovelli and Beatrice Detti and Daniele Santini and Alessandra Mosca and Franco Morelli and Giuseppe Fornarini and {De Giorgi}, Ugo and Cristina Masini and Luca Galli",

year = "2018",

month = aug,

day = "1",

doi = "10.21873/anticanres.12807",

language = "Non definita",

volume = "38",

pages = "4913--4918",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

}

TY - JOUR

T1 - Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience.

AU - Sbrana, Andrea

AU - Biasco, Elisa

AU - Paolieri, Federico

AU - Palesandro, Erica

AU - Caserta, Claudia

AU - Iacovelli, Roberto

AU - Detti, Beatrice

AU - Santini, Daniele

AU - Mosca, Alessandra

AU - Morelli, Franco

AU - Fornarini, Giuseppe

AU - De Giorgi, Ugo

AU - Masini, Cristina

AU - Galli, Luca

PY - 2018/8/1

Y1 - 2018/8/1

N2 - The specific characteristics of patients who are most likely to benefit from pazopanib therapy are still uncertain. We report on the results of an Italian multicenter, retrospective analysis investigating the factors associated with longer response to first-line pazopanib in patients with metastatic renal cell carcinoma. Adult patients were considered if they had received treatment with pazopanib (800 mg/day) for >12 months in the first-line setting. In total, 112 patients were evaluated. Median duration of pazopanib treatment was 22.6 months (IQR 17.8 months). Median PFS was 22.6 months (95%CI= 20.2-25.0). Eighty-three patients (74.1%) had a PFS ≥18 months. Median OS was 32.9 months (95%CI=30.2-35.6). At statistical analysis, only PS score (1+ vs. 0) was significantly associated with PFS (HR=1.76; 95%CI=1.02-3.05; p=0.04). Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0.

AB - The specific characteristics of patients who are most likely to benefit from pazopanib therapy are still uncertain. We report on the results of an Italian multicenter, retrospective analysis investigating the factors associated with longer response to first-line pazopanib in patients with metastatic renal cell carcinoma. Adult patients were considered if they had received treatment with pazopanib (800 mg/day) for >12 months in the first-line setting. In total, 112 patients were evaluated. Median duration of pazopanib treatment was 22.6 months (IQR 17.8 months). Median PFS was 22.6 months (95%CI= 20.2-25.0). Eighty-three patients (74.1%) had a PFS ≥18 months. Median OS was 32.9 months (95%CI=30.2-35.6). At statistical analysis, only PS score (1+ vs. 0) was significantly associated with PFS (HR=1.76; 95%CI=1.02-3.05; p=0.04). Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Angiogenesis Inhibitors, therapeutic use

KW - Carcinoma, Renal Cell, drug therapy

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Italy

KW - Kidney Neoplasms, drug therapy

KW - Male

KW - Middle Aged

KW - Pyrimidines, therapeutic use

KW - Receptors, Vascular Endothelial Growth Factor, antagonists & inhibitors

KW - Retrospective Studies

KW - Sulfonamides, therapeutic use

KW - first-line

KW - mRCC

KW - pazopanib

KW - response

U2 - 10.21873/anticanres.12807

DO - 10.21873/anticanres.12807

M3 - Articolo

SN - 0250-7005

VL - 38

SP - 4913

EP - 4918

JO - Anticancer Research

JF - Anticancer Research

ER -